Last reviewed · How we verify
optimal medical therapy
At a glance
| Generic name | optimal medical therapy |
|---|---|
| Also known as | intensive medical therapy, OMT, MOdern medical therapy, angiotensin receptor blockers, mineralocorticoid receptor antagonists |
| Sponsor | Seung-Jung Park |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (PHASE1)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years (NA)
- CANF-Comb-II PET-MR in Atherosclerosis Multisite
- The Nordic Baltic Chronic Total Occlusion (CTO) Arrhythmia Study (NA)
- The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion (NA)
- Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- optimal medical therapy CI brief — competitive landscape report
- optimal medical therapy updates RSS · CI watch RSS
- Seung-Jung Park portfolio CI